Closed
Source verified July 19, 2026
Clinical Evaluation and Assessment of AI-enabled Transfusion Decision Support Systems for Personalized Trauma Care: Phase II Study
AI-guided trauma transfusion research program
Offered by
Funding available
Varies by project
Deadline
Closed
Location
Canada
Overview
Clinical Evaluation and Assessment of AI-enabled Transfusion Decision Support Systems for Personalized Trauma Care: Phase II Study supports multidisciplinary research teams with 255,000 $ in 2026-2027 and 145,000 $ in 2027-2028 to validate AI models for personalized trauma transfusion care. Eligible work includes prospective and retrospective validation, real-time point-of-care data integration, and model refinement.
Find open grants for your business
Explore open funding programs that match your business and project.
At a glance
Funding available
Financing goals
- Increase performance through digital transformation
- Develop a new product or service
- Conduct research and development activities
Eligible Funding
- Varies by project
Funds Providers
Eligible candidates
Eligible Industries
- All industries
Location
- Canada
Legal structures
- All legal structures
Annual revenue
- All revenue ranges
Organisation size
- All organization sizes
Audience
- All groups
Next Steps
1
Determine your project
2
Validate your eligibility
Activities funded
- Validate and refine trauma transfusion decision-support models using prospective and retrospective data.
- Integrate real-time point-of-care data from ROTEM, FloPatch and/or point-of-care INR systems.
- Develop a real-time transfusion decision-making prototype.
- Evaluate model ability to predict massive hemorrhage protocol activation, transfusion needs, and patient outcomes within 24 hours of injury.
Documents Needed
- Research funding application form
Official resources
Eligibility
Who is eligible?
- Multidisciplinary research teams.
- Teams affiliated with at least one Level 1 trauma center.
- Teams with expertise in trauma resuscitation, AI and machine learning, and clinical trial design.
- Teams with access to high-performance computing resources and large military and civilian trauma datasets.
How to apply
- Download and submit the research funding application form.
Processing and Agreement
- Collaborate with the RDDC-CRT research team.
- Attend project meetings to provide updates and preliminary results.
- Submit regular progress reports in a timely manner, as needed.
- Collect real-time point-of-service datasets and share anonymized data with RDDC-CRT.
- Obtain research ethics board approval from an accredited Canadian institution before funds are released.
Contacts
Frequently Asked Questions about the Clinical Evaluation and Assessment of AI-enabled Transfusion Decision Support Systems for Personalized Trauma Care: Phase II Study Program
What is the Clinical Evaluation and Assessment of AI-enabled Transfusion Decision Support Systems for Personalized Trauma Care: Phase II Study?
Clinical Evaluation and Assessment of AI-enabled Transfusion Decision Support Systems for Personalized Trauma Care: Phase II Study supports multidisciplinary research teams with 255,000 $ in 2026-2027 and 145,000 $ in 2027-2028 to validate AI models for personalized trauma transfusion care. Eligible work includes prospective and retrospective validation, real-time point-of-care data integration, and model refinement.
Who is eligible for the Clinical Evaluation and Assessment of AI-enabled Transfusion Decision Support Systems for Personalized Trauma Care: Phase II Study program?
To be eligible for the Clinical Evaluation and Assessment of AI-enabled Transfusion Decision Support Systems for Personalized Trauma Care: Phase II Study program, you must:
Must be affiliated with at least one Level 1 trauma center.
Must include a multidisciplinary team led by a principal physician with trauma care expertise.
Must have a clearly defined and feasible plan for model validation, refinement, and clinical implementation.
What expenses are eligible under Clinical Evaluation and Assessment of AI-enabled Transfusion Decision Support Systems for Personalized Trauma Care: Phase II Study?
Validate and refine trauma transfusion decision-support models using prospective and retrospective data.
Integrate real-time point-of-care data from ROTEM, FloPatch and/or point-of-care INR systems.
Develop a real-time transfusion decision-making prototype.
Evaluate model ability to predict massive hemorrhage protocol activation, transfusion needs, and patient outcomes within 24 hours of injury.
Who can I contact for more information about the Clinical Evaluation and Assessment of AI-enabled Transfusion Decision Support Systems for Personalized Trauma Care: Phase II Study?
You can contact Veterans Affairs Canada (VAC) by email at research-recherche@veterans.gc.ca.
Where is the Clinical Evaluation and Assessment of AI-enabled Transfusion Decision Support Systems for Personalized Trauma Care: Phase II Study available?
The Clinical Evaluation and Assessment of AI-enabled Transfusion Decision Support Systems for Personalized Trauma Care: Phase II Study program is available across Canada.
Is the Clinical Evaluation and Assessment of AI-enabled Transfusion Decision Support Systems for Personalized Trauma Care: Phase II Study a grant, loan, or tax credit?
Clinical Evaluation and Assessment of AI-enabled Transfusion Decision Support Systems for Personalized Trauma Care: Phase II Study is a Grant and Funding
Who are the financial supporters of the Clinical Evaluation and Assessment of AI-enabled Transfusion Decision Support Systems for Personalized Trauma Care: Phase II Study?
Clinical Evaluation and Assessment of AI-enabled Transfusion Decision Support Systems for Personalized Trauma Care: Phase II Study is funded by Veterans Affairs Canada (VAC)